IATDMCT Congress 2026, Rennes

From 27–30 September 2026 I attended the joint congress of the IATDMCT and the French Society of Pharmacology and Therapeutics (SFPT) in Rennes. There I presented our abstract on proton pump inhibitors (PPIs) and lorlatinib-induced hyperlipidemia. About 70% of patients on lorlatinib develop hyperlipidemia, which is linked to higher peak concentrations (C_{max}). Based on the results of interaction studies, PPIs lower lorlatinib C_{max} by ~30% without reducing total exposure. In 56 patients with ALK- or ROS1-positive NSCLC from our retrospective biomarker study, PPI use was independently associated with a smaller rise in cholesterol throughout the treatment. PPIs may therefore offer a simple option for patients who are refractory or intolerant to lipid-lowering therapy.

The congress also let me meet international researchers working on TDM of small molecule inhibitors, which may lead to future collaborations. I thank the NRS for the travel grant that made this visit possible.



